麻豆传媒

Neurology >

Multiple Sclerosis

News, opinions and meeting coverage in neurology.

Getting a Handle on Benign MS

Prevalence varies by definition; agreed that disease progression varies widely

Vaccines Tied to Relapses in Neuromyelitis Optica

Retrospective review finds protective factor in immunotherapy

Revised McDonald Diagnostic Criteria Revealed

Recommends using OCBs, both symptomatic and asymptomatic lesions to diagnose MS

FDA Panel Backs New Warning for Gadolinium Contrast Agents

Manufacturers could be required to conduct new studies

Lymphoma Case Reported in MS Patient on Aubagio

First case in medical literature, more found in global surveillance reports

PPAR-Gamma Drug May Work in MS

In phase II study, drug diminished inflammatory lesions & cortical atrophy

McDonald Criteria for MS May Incorporate CSF Testing

Revision committee finds OCB testing may be useful in specific cases

NEPAD: Better Endpoint for Progressive MS Trials?

Tweak to 'no evidence of disease activity' standard stiffens criteria for progression

New Hints that Vitamin D Helps MS Patients

Two randomized trials miss endpoints but still strongly suggest benefit

Is 'No Evidence of Disease Activity' a Misnomer in MS?

Many patients still show signs of active disease despite meeting current NEDA criteria

'This is a Quadfecta!' What We Heard This Week

Quotable quotes from 麻豆传媒's sources

FDA Again Warns on Balloon Angioplasty for Neurologic Disorders

Says transvascular autonomic modulation is off-label and dangerous

Fatigue, Leg Dysfunction Predict Multiple Sclerosis Progression

Both associated with subsequent conversion to secondary progressive MS

European MS Guidance Taking Shape

ECTRIMS teases the first-ever MS drug guideline

Remyelinating Drug Flops in MS

Large placebo response, 'inverted U-shaped' dose-response in phase II trial

Registry Data: Lemtrada More Effective than Competing MS Tx

Better than fingolimod or interferon; comparable to natalizumab

New Ampyra Trial Bolsters MS Efficacy Claims

Walking ability, as reported by patients, significantly improved

Fluoxetine Flops as Progressive MS Therapy

Trial may have been underpowered to detect a benefit

Rituximab Bests MS Drugs in Swedish Registry

Rituximab offered drug survival advantage over fingolimod, natalizumab

HIV Drug Fails in Small MS Trial

Casts doubt on novel theory of MS etiology

Home-Based DVD May Motivate Seniors With MS to Exercise

Patients reported improvements in physical fitness, self-confidence

Studies Try to Estimate MS Drug Prices

Meds are expensive but push other costs down

Lemtrada Offers Long-Term Stability in MS Patients

Mean change in EDSS score was only +0.06

Lymphopenia Risk Factors to Watch With DMF

Age, race, baseline lymphocytes, overweight, & vitamin D levels included

Tysabri No Help in SPMS

Drug didnt reduce disability progression but may benefit upper limb function

Novel Drug Bests Interferon at Halting MS Activity

Nearly half of patients on ocrelizumab achieved no evidence of disease activity (NEDA)

Biogen Reports Another Tecfidera PML Case

Non-fatal case is the second one for the oral MS drug.

Novel MS Drug Offers Good Functional Outcomes

Daclizumab HYP beats interferon for patient-centered outcomes

No Surprises with Tysabri-Tecfidera Switch

Discontinuation rates for both agents were in line with those seen in clinical trials

Ballroom Dance a Boon to MS Patients

A small study finds ballroom dance -- waltz, salsa, foxtrot, and others -- may improve function in MS patients.

Does a Cocktail a Day Keep MS Symptoms at Bay?

Patients consuming more of the hard stuff had lower EDSS scores.

Seizure Drug May Help in MS Eye Disease

Phenytoin shows promise for slowing neurodegeneration in optic neuritis.

An 80-Proof Antidote for MS Disability?

Patients consuming more of the hard stuff had lower EDSS scores.

Increasing Tysabri Dosing Interval May Cut PML Risk

No sacrifice of efficacy seen in retrospective analysis.

Novel Drug for Cramping Shows Promise in Early Trial

Could benefit patients with MS spasticity and cervical dystonia.

Skull Size Tied to Disability Risk in MS

BOSTON -- Multiple sclerosis patients with larger intracranial volumes -- a measure of their lifetime maximal brain size -- scored better on cognition and physical function tests than those with smaller skull sizes.

Multiple Sclerosis Risk Tied to Some OCs

BOSTON -- Women using combined oral contraceptives containing norethindrone or levonorgestrel were substantially more likely to develop multiple sclerosis than those not on "The Pill."

Generic Copaxone for MS Passes Clinical Test

BOSTON -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it to win regulatory approval as a generic drug.

Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.

Dalfampridine: Not Just a Walking Aid

DALLAS -- Extended-release dalfampridine (Ampyra) is approved for boosting walking speed in multiple sclerosis patients, but its benefits extend to other aspects of physical function, according to a small study reported here.

鈥�

6